Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dexrazoxane
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : CNX Therapeutics
Deal Size : Undisclosed
Deal Type : Divestment
Clinigen Divests Global Rights to Four Cancer Support Therapies to CNX Therapeutics
Details : Under the terms of the divestment, Clinigen will divest four medicines, Cardioxane (dexrazoxane), Savene, Totect and Ethyol, all of which help mitigate the side effects patients may experience when treated with other cancer therapies, to CNX Therapeutics...
Brand Name : Cardioxane
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 10, 2023
Lead Product(s) : Dexrazoxane
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : CNX Therapeutics
Deal Size : Undisclosed
Deal Type : Divestment
Lead Product(s) : Dexrazoxane
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Totect® now can be used for reducing the incidence and severity of cardiomyopathy associated with doxorubicin in women with breast cancer who have received a cumulative doxorubicin dose of 300 mg/m² and who will continue to receive doxorubicin therapy.
Brand Name : Totect
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 10, 2020
Lead Product(s) : Dexrazoxane
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?